Key Findings:  The β-caryophyllene group showed significant improvement in nausea and epigastric pain, as well as a decrease in the serum IL-1β levels. β-caryophyllene improves dyspepsia symptoms and can be considered a useful supplementary treatment for gastrointestinal disease.
Type of Study:  Double Blind Clinical Trial
Study Sample Size:  66
Study Result:  Positive
Study Location(s):  South Korea
Year of Pub:  2019
Cannabinoids Studied: 
Phytocannabinoid Source:  Not Applicable
Terpenes Studied:  ß-Caryophyllene